Cargando…

Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA

Hepatitis C Virus (HCV) genotype (GT) 6 demonstrates maximum genomic diversity out of all the known genotypes of HCV, attributable to its inherent intra-genotype and inter-genotype recombination property. This is the most common genotype seen in HCV/HIV co-infected cases. HIV/HCV co-infection is lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ekta, Samal, Jasmine, Pandey, Amit, Singh, Gaurav, Gupta, Hajra A. S., Agarwal, Reshu, Sharma, Manoj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146731/
https://www.ncbi.nlm.nih.gov/pubmed/35632686
http://dx.doi.org/10.3390/v14050944
_version_ 1784716634996342784
author Gupta, Ekta
Samal, Jasmine
Pandey, Amit
Singh, Gaurav
Gupta, Hajra A. S.
Agarwal, Reshu
Sharma, Manoj Kumar
author_facet Gupta, Ekta
Samal, Jasmine
Pandey, Amit
Singh, Gaurav
Gupta, Hajra A. S.
Agarwal, Reshu
Sharma, Manoj Kumar
author_sort Gupta, Ekta
collection PubMed
description Hepatitis C Virus (HCV) genotype (GT) 6 demonstrates maximum genomic diversity out of all the known genotypes of HCV, attributable to its inherent intra-genotype and inter-genotype recombination property. This is the most common genotype seen in HCV/HIV co-infected cases. HIV/HCV co-infection is linked with increased genetic diversity in HCV structural genes. The detailed information on the distribution of HCV GT6, its subtypes, and resistance to currently available antiviral drugs is limited in the Indian subcontinent. Therefore, in this single-center retrospective cross-sectional study, we aimed to map the occurrence of HCV GT6, its subtypes and resistance-associated substitution (RAS), and its correlation with antiviral treatment response in HCV-infected patients. From a cohort of 2052 HCV-infected patients, the overall prevalence of GT6 was 2.5% (n = 53), with a maximum of 81.1% (n = 43) seen in HCV/HIV co-infected patients. Nine different subtypes, 6a, 6b, 6f, 6i, 6n, 6u, 6v, 6w, and 6xa, were detected in the Indian population for the first time, with a predominance of 6xa (41.5%), a rare subtype, followed by 6n (39.6%). The phylogenetic analysis by the neighbor-joining method revealed three prominent viral clades, 6v, 6n, and 6xa–6u. The baseline (before treatment initiation) plasma samples of all GT6-infected patients were retrieved from −80 °C and a part of the NS5a and NS5b region of the viral genome was analyzed for the presence of RAS. No RASs were seen in the NS5b region, while in two patients (3.7%) RASs were seen at baseline in the NS5a region of the virus. Sustained viral response (SVR) was attained in 81% (n = 43) of patients. No difference in GT6 subtype distribution or occurrence of RAS was seen between mono-infected HCV and HIV/HCV co-infected cases. Our study revealed that RAS at baseline did not influence the attainment of SVR and the currently available antiviral therapy is effective against GT6 mono-infected and HIV/HCV co-infected patients.
format Online
Article
Text
id pubmed-9146731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91467312022-05-29 Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA Gupta, Ekta Samal, Jasmine Pandey, Amit Singh, Gaurav Gupta, Hajra A. S. Agarwal, Reshu Sharma, Manoj Kumar Viruses Communication Hepatitis C Virus (HCV) genotype (GT) 6 demonstrates maximum genomic diversity out of all the known genotypes of HCV, attributable to its inherent intra-genotype and inter-genotype recombination property. This is the most common genotype seen in HCV/HIV co-infected cases. HIV/HCV co-infection is linked with increased genetic diversity in HCV structural genes. The detailed information on the distribution of HCV GT6, its subtypes, and resistance to currently available antiviral drugs is limited in the Indian subcontinent. Therefore, in this single-center retrospective cross-sectional study, we aimed to map the occurrence of HCV GT6, its subtypes and resistance-associated substitution (RAS), and its correlation with antiviral treatment response in HCV-infected patients. From a cohort of 2052 HCV-infected patients, the overall prevalence of GT6 was 2.5% (n = 53), with a maximum of 81.1% (n = 43) seen in HCV/HIV co-infected patients. Nine different subtypes, 6a, 6b, 6f, 6i, 6n, 6u, 6v, 6w, and 6xa, were detected in the Indian population for the first time, with a predominance of 6xa (41.5%), a rare subtype, followed by 6n (39.6%). The phylogenetic analysis by the neighbor-joining method revealed three prominent viral clades, 6v, 6n, and 6xa–6u. The baseline (before treatment initiation) plasma samples of all GT6-infected patients were retrieved from −80 °C and a part of the NS5a and NS5b region of the viral genome was analyzed for the presence of RAS. No RASs were seen in the NS5b region, while in two patients (3.7%) RASs were seen at baseline in the NS5a region of the virus. Sustained viral response (SVR) was attained in 81% (n = 43) of patients. No difference in GT6 subtype distribution or occurrence of RAS was seen between mono-infected HCV and HIV/HCV co-infected cases. Our study revealed that RAS at baseline did not influence the attainment of SVR and the currently available antiviral therapy is effective against GT6 mono-infected and HIV/HCV co-infected patients. MDPI 2022-04-30 /pmc/articles/PMC9146731/ /pubmed/35632686 http://dx.doi.org/10.3390/v14050944 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Gupta, Ekta
Samal, Jasmine
Pandey, Amit
Singh, Gaurav
Gupta, Hajra A. S.
Agarwal, Reshu
Sharma, Manoj Kumar
Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
title Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
title_full Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
title_fullStr Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
title_full_unstemmed Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
title_short Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
title_sort treatment response and drug resistance profiling of genotype 6 of hepatitis c virus in hcv/hiv co-infected patients: a pilot study from india
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146731/
https://www.ncbi.nlm.nih.gov/pubmed/35632686
http://dx.doi.org/10.3390/v14050944
work_keys_str_mv AT guptaekta treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia
AT samaljasmine treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia
AT pandeyamit treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia
AT singhgaurav treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia
AT guptahajraas treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia
AT agarwalreshu treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia
AT sharmamanojkumar treatmentresponseanddrugresistanceprofilingofgenotype6ofhepatitiscvirusinhcvhivcoinfectedpatientsapilotstudyfromindia